首页 > 最新文献

Journal of Infection and Chemotherapy最新文献

英文 中文
Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment. Bcl-2抑制剂venetoclax治疗急性髓系白血病患者侵袭性真菌疾病的预防策略
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-12-04 DOI: 10.1016/j.jiac.2024.12.005
Pengfei Li, Zhiming Luo, Jianchuan Deng

Patients with acute myeloid leukemia (AML) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality, including those who were received Venetoclax treatment. Venetoclax, a new oral Bcl-2 inhibitor, targets tumor cells' ability to induce apoptosis. It is the only one which is approved by Food and Drug Administration (FDA) for treating newly diagnosed AML patients who are 75 years of age or older and are ineligible for intensive induction chemotherapy due to existing comorbidities. It has been shown that venetoclax-based regimens raise the risk of invasive fungal diseases (IFD) for AML patients in clinical practice. Because it can lead to prolonged and profound neutropenia in AML patients, with IFD incidence rates ranging from 5.1 % to 32 %, resulting in higher mortality rates. Because of drug-drug interactions between Venetoclax and partial antifungal agents, to choose anti-fungal prophylaxis and to adjust the dosage of agents rationally for AML patients seems crucial to physicians to those who are undergoing venetoclax-based chemotherapy. Therefore, this review aims to summary the mechanism and characteristic of IFD in AML patients and provide practical clinical suggestions and details for the prophylaxis of IFD in AML patients suffering Venetoclax-based treatment.

急性髓性白血病(AML)患者发展为侵袭性真菌病(IFD)的风险很高,具有高发病率和可归因死亡率,包括接受Venetoclax治疗的患者。Venetoclax是一种新的口服Bcl-2抑制剂,靶向肿瘤细胞诱导凋亡的能力。它是美国食品和药物管理局(FDA)唯一批准用于治疗75岁及以上新诊断的AML患者,由于存在合并症而不适合进行强化诱导化疗。临床实践表明,基于venetoclax的方案增加了AML患者侵袭性真菌疾病(IFD)的风险。因为它可导致AML患者出现长时间和深度中性粒细胞减少,IFD的发病率从5.1%到32%不等,导致较高的死亡率。由于Venetoclax与部分抗真菌药物之间的药物相互作用,对于接受Venetoclax为基础的化疗的AML患者,选择抗真菌预防药物和合理调整药物剂量对医生来说至关重要。因此,本文旨在总结AML患者IFD发生的机制和特点,为使用venetoclax治疗的AML患者预防IFD提供实用的临床建议和细节。
{"title":"Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment.","authors":"Pengfei Li, Zhiming Luo, Jianchuan Deng","doi":"10.1016/j.jiac.2024.12.005","DOIUrl":"10.1016/j.jiac.2024.12.005","url":null,"abstract":"<p><p>Patients with acute myeloid leukemia (AML) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality, including those who were received Venetoclax treatment. Venetoclax, a new oral Bcl-2 inhibitor, targets tumor cells' ability to induce apoptosis. It is the only one which is approved by Food and Drug Administration (FDA) for treating newly diagnosed AML patients who are 75 years of age or older and are ineligible for intensive induction chemotherapy due to existing comorbidities. It has been shown that venetoclax-based regimens raise the risk of invasive fungal diseases (IFD) for AML patients in clinical practice. Because it can lead to prolonged and profound neutropenia in AML patients, with IFD incidence rates ranging from 5.1 % to 32 %, resulting in higher mortality rates. Because of drug-drug interactions between Venetoclax and partial antifungal agents, to choose anti-fungal prophylaxis and to adjust the dosage of agents rationally for AML patients seems crucial to physicians to those who are undergoing venetoclax-based chemotherapy. Therefore, this review aims to summary the mechanism and characteristic of IFD in AML patients and provide practical clinical suggestions and details for the prophylaxis of IFD in AML patients suffering Venetoclax-based treatment.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102576"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Descriptive analysis of safety and immunogenicity profiles of a 15-valent pneumococcal conjugate vaccine between subcutaneous and intramuscular administration in a phase 1 study of healthy Japanese infants (V114-028). 在一项针对日本健康婴儿的 1 期研究中,对皮下注射和肌肉注射 15 价肺炎球菌结合疫苗的安全性和免疫原性进行描述性分析 (V114-028)。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-10-09 DOI: 10.1016/j.jiac.2024.10.007
Keiko Wan, Masayoshi Shirakawa, Miyuki Sawata

Introduction: Subcutaneous (SC) administration is typically used for pediatric inactivated vaccines in Japan, whereas intramuscular (IM) administration is used outside Japan. We previously reported the safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine (PCV), administered subcutaneously and intramuscularly in a Japanese phase 1 study (V114-028). Here, we report secondary descriptive analyses on V114 groups of the study to further assess the safety and immunogenicity profiles of V114 between the administration routes.

Methods: A total of 133 healthy Japanese infants were randomized to receive V114-SC (n = 44), V114-IM (n = 45), or PCV13-SC (n = 44) at approximately 3, 4, 5, and 12-15 months of age. Adverse events (AEs) from Days 1-14 post-vaccination and vaccine-related serious AEs from Day 1 to 1-month post-dose 4 were reported. Serotype-specific immunoglobulin G (IgG) responses were measured across the vaccination series.

Results: Proportions of participants with solicited systemic AEs (irritability, somnolence, decreased appetite, and urticaria) and pyrexia were generally comparable between the groups. Compared with V114-SC, patients receiving V114-IM had a lower incidence of irritability and somnolence, and higher incidence of decreased appetite. Proportion of participants with solicited injection-site erythema was lower with V114-IM (82.2%) than V114-SC (100.0%). Those with other solicited injection-site AEs (induration, swelling, and pain) were generally comparable between the groups, with lower observed proportions with V114-IM. Serotype-specific IgG responses were also generally comparable between the groups, including at pre-toddler dose.

Conclusions: These results suggest the utility of IM administration as an option for V114 vaccination in Japanese infants.

简介:在日本,小儿灭活疫苗通常采用皮下注射 (SC),而在日本以外则采用肌肉注射 (IM)。我们曾在日本的一项 1 期研究(V114-028)中报告了 15 价肺炎球菌结合疫苗 (PCV) V114 皮下注射和肌肉注射的安全性和免疫原性。在此,我们报告该研究中 V114 组的二次描述性分析,以进一步评估 V114 不同给药途径的安全性和免疫原性概况:共有 133 名健康的日本婴儿被随机分配到 V114-SC(44 人)、V114-IM(45 人)或 PCV13-SC(44 人)组,分别在婴儿约 3、4、5 和 12-15 个月大时给药。报告了接种后第 1-14 天的不良事件 (AE) 以及第 1 天至第 4 剂后 1 个月的疫苗相关严重不良事件。测量了整个接种系列的血清型特异性免疫球蛋白 G (IgG) 反应:结果:两组接种者出现全身性不良反应(烦躁、嗜睡、食欲下降和荨麻疹)和发热的比例基本相当。与V114-SC相比,接受V114-IM治疗的患者烦躁和嗜睡的发生率较低,食欲下降的发生率较高。V114-IM患者出现注射部位红斑的比例(82.2%)低于V114-SC(100.0%)。两组中出现其他注射部位AE(压痕、肿胀和疼痛)的人数基本相当,但V114-IM观察到的比例较低。各组之间的血清型特异性 IgG 反应(包括幼儿期前的剂量)也基本相当:这些结果表明,在日本婴儿接种 V114 疫苗时,IM 给药是一种有效的选择。
{"title":"Descriptive analysis of safety and immunogenicity profiles of a 15-valent pneumococcal conjugate vaccine between subcutaneous and intramuscular administration in a phase 1 study of healthy Japanese infants (V114-028).","authors":"Keiko Wan, Masayoshi Shirakawa, Miyuki Sawata","doi":"10.1016/j.jiac.2024.10.007","DOIUrl":"10.1016/j.jiac.2024.10.007","url":null,"abstract":"<p><strong>Introduction: </strong>Subcutaneous (SC) administration is typically used for pediatric inactivated vaccines in Japan, whereas intramuscular (IM) administration is used outside Japan. We previously reported the safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine (PCV), administered subcutaneously and intramuscularly in a Japanese phase 1 study (V114-028). Here, we report secondary descriptive analyses on V114 groups of the study to further assess the safety and immunogenicity profiles of V114 between the administration routes.</p><p><strong>Methods: </strong>A total of 133 healthy Japanese infants were randomized to receive V114-SC (n = 44), V114-IM (n = 45), or PCV13-SC (n = 44) at approximately 3, 4, 5, and 12-15 months of age. Adverse events (AEs) from Days 1-14 post-vaccination and vaccine-related serious AEs from Day 1 to 1-month post-dose 4 were reported. Serotype-specific immunoglobulin G (IgG) responses were measured across the vaccination series.</p><p><strong>Results: </strong>Proportions of participants with solicited systemic AEs (irritability, somnolence, decreased appetite, and urticaria) and pyrexia were generally comparable between the groups. Compared with V114-SC, patients receiving V114-IM had a lower incidence of irritability and somnolence, and higher incidence of decreased appetite. Proportion of participants with solicited injection-site erythema was lower with V114-IM (82.2%) than V114-SC (100.0%). Those with other solicited injection-site AEs (induration, swelling, and pain) were generally comparable between the groups, with lower observed proportions with V114-IM. Serotype-specific IgG responses were also generally comparable between the groups, including at pre-toddler dose.</p><p><strong>Conclusions: </strong>These results suggest the utility of IM administration as an option for V114 vaccination in Japanese infants.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102539"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Symptoms of post COVID-19 condition and diseases/conditions diagnosed after COVID-19 in Japanese patients: A real-world study using a claims database. 日本患者 COVID-19 后的症状以及 COVID-19 后诊断出的疾病/病症:利用索赔数据库进行的真实世界研究。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-10-11 DOI: 10.1016/j.jiac.2024.10.008
Satoshi Kutsuna, Ryotaro Tajima, Genta Ito, Takuji Komeda, Hideyuki Miyauchi, Yoshitake Kitanishi

Background: More than 200 symptoms of post coronavirus disease (COVID-19) condition (PCC) impacting patients' quality of life have been reported. This study describes the symptoms of well-known PCC and diseases/conditions diagnosed after COVID-19 and analyzes the trends in well-known PCC according to the epidemic waves in the Japanese population.

Methods: Patients with a COVID-19 diagnosis in the JMDC claims database were matched 1:1 with individuals without COVID-19 diagnosis (controls) based on sex, year and month of birth, and risk factors for aggravation. The first month of COVID-19 diagnosis from January 2020-March 2022 was the index month, and the observation period was from July 2019 to 6 months from the index month (patients) and July 2019-September 2022 (controls).

Results: Of 263,456 each of patients and controls after matching, 51.8 % were aged 18-49 years, 56.3 % were male, and 24.5 % had risk factors for aggravation. One in 18 patients experienced well-known PCC 2-3 months after severe acute respiratory syndrome cornonavirus 2 infection, with the highest odds ratio (OR) being for pulmonary thromboembolism (29.37), followed by smell/taste disorder (13.34) and respiratory failure (8.28). Some of the common diseases/conditions diagnosed after COVID-19 comprised those of the genitourinary system, eye and adnexa, and ear and mastoid process and certain infectious and parasitic diseases. Overall, the risk difference decreased from the first to the sixth wave, but the OR was >1.00 for most symptoms even during the sixth wave.

Conclusions: PCC symptoms showed a declining trend over time but persisted. Physicians and patients need to recognize PCC symptoms.

背景:已有 200 多种影响患者生活质量的 COVID-19 后疾病(PCC)症状被报道。本研究描述了知名 PCC 的症状和 COVID-19 诊断后的疾病/病症,并根据日本人口中的流行病浪潮分析了知名 PCC 的趋势:方法:根据性别、出生年份和月份以及病情恶化的风险因素,将日本疾病预防控制中心索赔数据库中确诊为冠状病毒疾病(COVID-19)的患者与未确诊为 COVID-19 的患者(对照组)进行 1:1 配对。2020年1月至2022年3月期间诊断出COVID-19的第一个月为指标月,观察期为2019年7月至指标月起的6个月(患者)和2019年7月至2022年9月(对照组):在配对后的263 456名患者和对照组中,51.8%的患者年龄在18-49岁之间,56.3%为男性,24.5%存在病情加重的风险因素。每 18 名患者中就有 1 人在感染 SARS-CoV-2 2-3 个月后出现知名的 PCC,其中肺血栓栓塞症的几率比(OR)最高(29.37),其次是嗅觉/味觉障碍(13.34)和呼吸衰竭(8.28)。COVID-19 后诊断出的一些常见疾病/病症包括泌尿生殖系统、眼睛和附件、耳和乳突以及某些传染病和寄生虫病。总体而言,从第一波到第六波,风险差异有所减小,但即使在第六波中,大多数症状的 OR 也大于 1.00:结论:随着时间的推移,PCC 症状呈下降趋势,但仍持续存在。医生和患者需要识别 PCC 症状。
{"title":"Symptoms of post COVID-19 condition and diseases/conditions diagnosed after COVID-19 in Japanese patients: A real-world study using a claims database.","authors":"Satoshi Kutsuna, Ryotaro Tajima, Genta Ito, Takuji Komeda, Hideyuki Miyauchi, Yoshitake Kitanishi","doi":"10.1016/j.jiac.2024.10.008","DOIUrl":"10.1016/j.jiac.2024.10.008","url":null,"abstract":"<p><strong>Background: </strong>More than 200 symptoms of post coronavirus disease (COVID-19) condition (PCC) impacting patients' quality of life have been reported. This study describes the symptoms of well-known PCC and diseases/conditions diagnosed after COVID-19 and analyzes the trends in well-known PCC according to the epidemic waves in the Japanese population.</p><p><strong>Methods: </strong>Patients with a COVID-19 diagnosis in the JMDC claims database were matched 1:1 with individuals without COVID-19 diagnosis (controls) based on sex, year and month of birth, and risk factors for aggravation. The first month of COVID-19 diagnosis from January 2020-March 2022 was the index month, and the observation period was from July 2019 to 6 months from the index month (patients) and July 2019-September 2022 (controls).</p><p><strong>Results: </strong>Of 263,456 each of patients and controls after matching, 51.8 % were aged 18-49 years, 56.3 % were male, and 24.5 % had risk factors for aggravation. One in 18 patients experienced well-known PCC 2-3 months after severe acute respiratory syndrome cornonavirus 2 infection, with the highest odds ratio (OR) being for pulmonary thromboembolism (29.37), followed by smell/taste disorder (13.34) and respiratory failure (8.28). Some of the common diseases/conditions diagnosed after COVID-19 comprised those of the genitourinary system, eye and adnexa, and ear and mastoid process and certain infectious and parasitic diseases. Overall, the risk difference decreased from the first to the sixth wave, but the OR was >1.00 for most symptoms even during the sixth wave.</p><p><strong>Conclusions: </strong>PCC symptoms showed a declining trend over time but persisted. Physicians and patients need to recognize PCC symptoms.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102540"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Burkholderia cepacia contaminating fresh frozen plasma causing transfusion transmitted bacterial infection. 伯克霍尔德氏菌污染新鲜冰冻血浆导致输血传播细菌感染。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-10-24 DOI: 10.1016/j.jiac.2024.10.013
Vithiya G, P Shunmuga Sundaram, T Rajendran

Bacterial contamination of plasma is unusual owing to frozen storage nevertheless reported. We report a case of transfusion transmitted infection due to Burkholderia cepacia contaminating fresh frozen plasma. A 31 year old male with decompensated chronic liver disease presented with breathlessness due to pleural effusion. Due to elevated prothrombin time, fresh frozen plasma was infused. After ten minutes of transfusion, he became febrile, tachypnoeic and transfusion was stopped. Plasma bag and blood cultures from patient grew B. cepacia. He became hemodynamically unstable due to underlying disease and died after a week.

由于冷冻储存的原因,血浆受到细菌污染的情况并不常见。我们报告了一例因新鲜冰冻血浆污染伯克霍尔德氏菌而导致的输血传播感染病例。一名患有慢性肝病失代偿期的 31 岁男性因胸腔积液出现呼吸困难。由于凝血酶原时间升高,他输注了新鲜冰冻血浆。输注 10 分钟后,他开始发热、心跳过速,输血随即停止。患者的血浆袋和血液培养物中都检出了头孢杆菌。由于潜在的疾病,他的血流动力学变得不稳定,一周后死亡。
{"title":"Burkholderia cepacia contaminating fresh frozen plasma causing transfusion transmitted bacterial infection.","authors":"Vithiya G, P Shunmuga Sundaram, T Rajendran","doi":"10.1016/j.jiac.2024.10.013","DOIUrl":"10.1016/j.jiac.2024.10.013","url":null,"abstract":"<p><p>Bacterial contamination of plasma is unusual owing to frozen storage nevertheless reported. We report a case of transfusion transmitted infection due to Burkholderia cepacia contaminating fresh frozen plasma. A 31 year old male with decompensated chronic liver disease presented with breathlessness due to pleural effusion. Due to elevated prothrombin time, fresh frozen plasma was infused. After ten minutes of transfusion, he became febrile, tachypnoeic and transfusion was stopped. Plasma bag and blood cultures from patient grew B. cepacia. He became hemodynamically unstable due to underlying disease and died after a week.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102545"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular epidemiology and clinical characteristics of Staphylococcus aureus bacteremia in Japanese adults. 日本成人金黄色葡萄球菌菌血症的分子流行病学和临床特征。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-11-12 DOI: 10.1016/j.jiac.2024.11.005
Kohsuke Tsubaki, Kei Kasahara, Tomoko Asada, Ryuichi Nakano, Akiyo Nakano, Keiichi Mikasa, Masahiko Kawaguchi, Hisakazu Yano

Introduction: Staphylococcus aureus bacteremia (SAB), especially when caused by methicillin-resistant S. aureus (MRSA), is of considerable clinical importance. In recent years, the proportion of MRSA among S. aureus has decreased, and a relative increase in the proportion of methicillin-susceptible S. aureus (MSSA) has been observed. It is therefore necessary to consider both MRSA and MSSA when assessing the microbiological and clinical significance of SAB.

Materials and methods: We included SAB cases from the Nara Medical University Hospital between January 2015 and February 2017. We performed drug susceptibility testing, toxicity gene analysis, multilocus sequence typing (MLST), and polymerase chain reaction-based open reading frame typing (POT) of stored strains to integrate clinical and bacteriological characteristics.

Results: There were 90 cases during the experimental period (42 MRSA and 48 MSSA), with 30-day mortality rates of 19 % for MRSA and 10.4 % for MSSA. Deaths were more frequently complicated by septic shock and disseminated intravascular coagulation. MLST studies showed that ST8, ST764, ST1, and ST15 were prevalent in the MRSA group, whereas ST5, ST188, and ST12 were prevalent in MSSA. Infective endocarditis cases had a long time from onset to the initiation of effective antimicrobials and were all MSSA. MLST and POT results correlated well, and POT appeared to have better discriminatory power.

Conclusions: The severity and mortality of SAB, along with the microbiological characteristics of causative isolates, vary by location and time. Continued studies integrating clinical and microbiological investigations are thus needed.

导言:金黄色葡萄球菌菌血症(SAB),尤其是由耐甲氧西林金黄色葡萄球菌(MRSA)引起的 SAB,具有相当重要的临床意义。近年来,金黄色葡萄球菌中 MRSA 的比例有所下降,而甲氧西林耐药金黄色葡萄球菌(MSSA)的比例则相对上升。因此,在评估 SAB 的微生物学和临床意义时,有必要同时考虑 MRSA 和 MSSA:我们纳入了奈良医科大学医院 2015 年 1 月至 2017 年 2 月间的 SAB 病例。我们对储存的菌株进行了药敏试验、毒性基因分析、多焦点序列分型(MLST)和基于聚合酶链式反应的开放读码框分型(POT),以整合临床和细菌学特征:实验期间共有 90 例病例(42 例 MRSA 和 48 例 MSSA),30 天内 MRSA 死亡率为 19%,MSSA 死亡率为 10.4%。死亡病例多并发脓毒性休克和弥散性血管内凝血。MLST 研究显示,MRSA 组中流行 ST8、ST764、ST1 和 ST15,而 MSSA 组中流行 ST5、ST188 和 ST12。感染性心内膜炎病例从发病到开始使用有效抗菌药物的时间较长,且均为 MSSA。MLST和POT结果相关性良好,POT似乎具有更好的鉴别力:结论:SAB 的严重程度和死亡率以及致病分离菌的微生物学特征因地点和时间而异。因此,有必要继续开展综合临床和微生物学调查的研究。
{"title":"Molecular epidemiology and clinical characteristics of Staphylococcus aureus bacteremia in Japanese adults.","authors":"Kohsuke Tsubaki, Kei Kasahara, Tomoko Asada, Ryuichi Nakano, Akiyo Nakano, Keiichi Mikasa, Masahiko Kawaguchi, Hisakazu Yano","doi":"10.1016/j.jiac.2024.11.005","DOIUrl":"10.1016/j.jiac.2024.11.005","url":null,"abstract":"<p><strong>Introduction: </strong>Staphylococcus aureus bacteremia (SAB), especially when caused by methicillin-resistant S. aureus (MRSA), is of considerable clinical importance. In recent years, the proportion of MRSA among S. aureus has decreased, and a relative increase in the proportion of methicillin-susceptible S. aureus (MSSA) has been observed. It is therefore necessary to consider both MRSA and MSSA when assessing the microbiological and clinical significance of SAB.</p><p><strong>Materials and methods: </strong>We included SAB cases from the Nara Medical University Hospital between January 2015 and February 2017. We performed drug susceptibility testing, toxicity gene analysis, multilocus sequence typing (MLST), and polymerase chain reaction-based open reading frame typing (POT) of stored strains to integrate clinical and bacteriological characteristics.</p><p><strong>Results: </strong>There were 90 cases during the experimental period (42 MRSA and 48 MSSA), with 30-day mortality rates of 19 % for MRSA and 10.4 % for MSSA. Deaths were more frequently complicated by septic shock and disseminated intravascular coagulation. MLST studies showed that ST8, ST764, ST1, and ST15 were prevalent in the MRSA group, whereas ST5, ST188, and ST12 were prevalent in MSSA. Infective endocarditis cases had a long time from onset to the initiation of effective antimicrobials and were all MSSA. MLST and POT results correlated well, and POT appeared to have better discriminatory power.</p><p><strong>Conclusions: </strong>The severity and mortality of SAB, along with the microbiological characteristics of causative isolates, vary by location and time. Continued studies integrating clinical and microbiological investigations are thus needed.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102555"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of easing COVID-19 strategies following downgrading of the national infectious disease category on COVID-19 occurrence among hospitalized patients in Japan. 国家传染病类别降级后放宽 COVID-19 策略对日本住院患者中 COVID-19 发生率的影响。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-07-06 DOI: 10.1016/j.jiac.2024.07.004
Miyuki Makino, Yoshio Takesue, Yasushi Murakami, Mika Morosawa, Miki Doi, Hitoshi Ogashiwa, Takashi Ueda, Kazuhiko Nakajima, Hiroyuki Sugiura, Yasuhiro Nozaki

Purpose: We aimed to evaluate the influence of easing COVID-19 preventive measures following its downgrading to a common infectious disease on COVID-19 occurrence among hospitalized patients.

Methods: Nosocomial occurrence of COVID-19 was compared between periods with national infectious disease category 5 versus the preceding category 2 equivalent. Changes in the revised manual included a shorter duration of work restrictions for infected health care practitioners (HCPs); no work restriction for HCPs exposed to SARS-CoV-2 with a negative test on days 1, 3 and 5; discontinuation of universal pre-admission screening; and pre-emptive isolation of patients without screening. Wearing an N95 mask and face shield was required in procedure/care with moderate-to high-risk contact.

Results: Although the mean monthly number of infected HCPs increased from 8.1 to 12.7 in the category 5 period (p = 0.034) and that of pre-admission screening decreased to one-fourth, the COVID-19 incidence in hospitalized patients remained similar between the two study periods (1.60 ± 5.59/month versus 1.40 ± 2.63/month, p = 0.358). Clusters, defined as ≥3 COVID-19 patients on the ward, were experienced twice in the preceding period and only once in the category 5 period. The index cases causing nosocomial SARS-CoV-2 transmission mostly involved rehabilitation therapists in the preceding period; five of six index cases were patients in the category 5 period. Following the expanded indication for N95 masks, neither SARS-CoV-2 transmission to patients nor transmission from infected patients was observed in HCPs for 1 year.

Conclusion: With sustained, enhanced standard precautions, easing prevention strategies could limit nosocomial SARS-CoV-2 infections.

目的:我们旨在评估 COVID-19 降级为常见传染病后放松预防措施对住院患者中 COVID-19 发生率的影响:方法:比较了国家五类传染病与之前的二类传染病之间的 COVID-19 非医院感染率。修订手册中的变化包括缩短受感染医护人员(HCPs)的工作限制时间;对暴露于 SARS-CoV-2 并在第 1、3 和 5 天检测呈阴性的医护人员不作工作限制;停止入院前的普遍筛查;以及对未经筛查的患者进行先期隔离。在接触中度至高度风险的程序/护理中必须佩戴 N95 口罩和面罩:尽管在第 5 类研究期间,受感染的 HCP 的月平均人数从 8.1 人增至 12.7 人(p=0.034),入院前筛查的人数降至四分之一,但住院患者的 COVID-19 感染率在两个研究期间保持相似(1.60±5.59/月对 1.40±2.63/月,p=0.358)。病房中 COVID-19 病例≥3 例即为集群病例,前一时期出现过两次集群病例,而在第 5 类研究期间仅出现过一次集群病例。导致 SARS-CoV-2 在院内传播的指数病例大多涉及前一时期的康复治疗师;6 个指数病例中有 5 个是第 5 类时期的患者。在扩大 N95 口罩的适用范围后,1 年内没有发现 SARS-CoV-2 传播到病人身上,也没有发现从感染病人身上传播的情况:结论:通过持续加强标准预防措施,简化预防策略可以限制 SARS-CoV-2 的院内感染。
{"title":"Influence of easing COVID-19 strategies following downgrading of the national infectious disease category on COVID-19 occurrence among hospitalized patients in Japan.","authors":"Miyuki Makino, Yoshio Takesue, Yasushi Murakami, Mika Morosawa, Miki Doi, Hitoshi Ogashiwa, Takashi Ueda, Kazuhiko Nakajima, Hiroyuki Sugiura, Yasuhiro Nozaki","doi":"10.1016/j.jiac.2024.07.004","DOIUrl":"10.1016/j.jiac.2024.07.004","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to evaluate the influence of easing COVID-19 preventive measures following its downgrading to a common infectious disease on COVID-19 occurrence among hospitalized patients.</p><p><strong>Methods: </strong>Nosocomial occurrence of COVID-19 was compared between periods with national infectious disease category 5 versus the preceding category 2 equivalent. Changes in the revised manual included a shorter duration of work restrictions for infected health care practitioners (HCPs); no work restriction for HCPs exposed to SARS-CoV-2 with a negative test on days 1, 3 and 5; discontinuation of universal pre-admission screening; and pre-emptive isolation of patients without screening. Wearing an N95 mask and face shield was required in procedure/care with moderate-to high-risk contact.</p><p><strong>Results: </strong>Although the mean monthly number of infected HCPs increased from 8.1 to 12.7 in the category 5 period (p = 0.034) and that of pre-admission screening decreased to one-fourth, the COVID-19 incidence in hospitalized patients remained similar between the two study periods (1.60 ± 5.59/month versus 1.40 ± 2.63/month, p = 0.358). Clusters, defined as ≥3 COVID-19 patients on the ward, were experienced twice in the preceding period and only once in the category 5 period. The index cases causing nosocomial SARS-CoV-2 transmission mostly involved rehabilitation therapists in the preceding period; five of six index cases were patients in the category 5 period. Following the expanded indication for N95 masks, neither SARS-CoV-2 transmission to patients nor transmission from infected patients was observed in HCPs for 1 year.</p><p><strong>Conclusion: </strong>With sustained, enhanced standard precautions, easing prevention strategies could limit nosocomial SARS-CoV-2 infections.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102464"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Four successive cases of human fasciolosis in Japan. 日本连续出现四例人类筋膜炎病例。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-07-25 DOI: 10.1016/j.jiac.2024.07.020
Ayako Kumabe, Asako Doi, Tsuyoshi Kitaura, Atsushi Katayama, Takanori Harada, Michimasa Ueda, Risa Matsuda, Madoka Ichikawa-Seki, Mio Tanaka, Chiho Kaneko, Ayako Yoshida, Hiroki Chikumi, Haruhiko Maruyama

Fasciolosis is a food-borne parasitic disease, caused by the large liver fluke, Fasciola. Humans acquire infection by ingesting fresh or undercooked water plants, on which infective metacercaria encyst. In spite of the rarity of the disease in Japan, we encountered four successive fasciolosis patients within a short period, who were all living in the same area. The patients were 70-82 years old, three females and the husband of one of the female patients. They started complaining of non-specific symptoms, such as fever, general fatigue, appetite loss, and abdominal pain, almost at the same time. All patients showed prominent peripheral blood eosinophilia, and the medical imaging indicated multiple hepatic lesions. No parasite eggs or worms were detected in any of the patients. Diagnosis was made serologically and they were treated with praziquantel and/or triclabendazole. No cattle or sheep were farmed in the area, but the wild sika deer, Cervus nippon, inhabited adjacent to the residential area. The intermediate host snail, Austropeplea ollula, were found near the residence of the patients, and one of the collected snails was positive for F. hepatica/gigantica hybrid type rediae. Our report should alarm the medical professionals for this rare and unfamiliar parasitic disease.

法氏囊病是一种食源性寄生虫病,由大型肝吸虫--法氏囊虫引起。人类通过摄入新鲜或未煮熟的水生植物感染该病。尽管这种疾病在日本非常罕见,但我们还是在短时间内连续遇到了四名法氏囊病患者,他们都生活在同一地区。患者年龄在 70-82 岁之间,其中三人为女性,一名女性患者的丈夫为男性。他们几乎在同一时间开始出现发热、全身乏力、食欲不振和腹痛等非特异性症状。所有患者的外周血嗜酸性粒细胞增多,医学影像显示肝脏有多处病变。所有患者体内均未检测到寄生虫卵或蠕虫。经血清学诊断,他们接受了吡喹酮和/或曲克菌唑治疗。该地区没有养殖牛羊,但野生梅花鹿(Cervus nippon)栖息在居民区附近。在患者住所附近发现了中间宿主蜗牛 Austropeplea ollula,其中一只采集到的蜗牛对 F. hepatica/gigantica 杂交红蜗牛呈阳性反应。我们的报告应引起医务人员对这种罕见而陌生的寄生虫病的警惕。
{"title":"Four successive cases of human fasciolosis in Japan.","authors":"Ayako Kumabe, Asako Doi, Tsuyoshi Kitaura, Atsushi Katayama, Takanori Harada, Michimasa Ueda, Risa Matsuda, Madoka Ichikawa-Seki, Mio Tanaka, Chiho Kaneko, Ayako Yoshida, Hiroki Chikumi, Haruhiko Maruyama","doi":"10.1016/j.jiac.2024.07.020","DOIUrl":"10.1016/j.jiac.2024.07.020","url":null,"abstract":"<p><p>Fasciolosis is a food-borne parasitic disease, caused by the large liver fluke, Fasciola. Humans acquire infection by ingesting fresh or undercooked water plants, on which infective metacercaria encyst. In spite of the rarity of the disease in Japan, we encountered four successive fasciolosis patients within a short period, who were all living in the same area. The patients were 70-82 years old, three females and the husband of one of the female patients. They started complaining of non-specific symptoms, such as fever, general fatigue, appetite loss, and abdominal pain, almost at the same time. All patients showed prominent peripheral blood eosinophilia, and the medical imaging indicated multiple hepatic lesions. No parasite eggs or worms were detected in any of the patients. Diagnosis was made serologically and they were treated with praziquantel and/or triclabendazole. No cattle or sheep were farmed in the area, but the wild sika deer, Cervus nippon, inhabited adjacent to the residential area. The intermediate host snail, Austropeplea ollula, were found near the residence of the patients, and one of the collected snails was positive for F. hepatica/gigantica hybrid type rediae. Our report should alarm the medical professionals for this rare and unfamiliar parasitic disease.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102480"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Culture-negative infective endocarditis due to Neisseria bacilliformis identified via 16S rRNA gene analysis from resected valve tissue: Case report and review of the literature. 通过对切除的瓣膜组织进行 16S rRNA 基因分析,发现奈瑟氏菌类杆菌引起的培养阴性感染性心内膜炎:病例报告和文献综述。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-08-28 DOI: 10.1016/j.jiac.2024.08.017
Yoshinori Takahashi, Junya Nakade, Yoshitaka Zaimoku, Naoki Watanabe, Tomohisa Watari, Yoshihito Otsuka, Yasunori Iwata, Hajime Kanamori

Blood culture-negative infective endocarditis (BCNE) has a poorer prognosis than culture-positive cases. Thus, it is crucial to determine the pathogenic microorganism using molecular diagnostic techniques, in addition to conventional techniques, including cultures of blood and/or resected valve tissue. Herein, we report a case of culture-negative infective endocarditis (IE) caused by Neisseria bacilliformis, as identified by 16S rRNA analysis of valve tissue. N. bacilliformis a non-gonococcal and non-meningococcal Neisseria species that partially comprises the oropharyngeal microbiome, and reports of invasive infections have increased recently. We conducted a literature review of IE caused by N. bacilliformis and found that beta-lactam antibiotics were effective with a relatively favorable prognosis. To the best of our knowledge, this is the first case of culture-negative IE in which N. bacilliformis was identified via 16S rRNA analysis.

与培养阳性病例相比,血培养阴性的感染性心内膜炎(BCNE)预后较差。因此,除了血液和/或切除的瓣膜组织培养等传统技术外,使用分子诊断技术确定病原微生物至关重要。在此,我们报告了一例培养阴性的感染性心内膜炎(IE)病例,该病例是通过对瓣膜组织进行 16S rRNA 分析而确定的奈瑟氏菌(Neisseria bacilliformis)引起的。巴氏奈瑟菌是一种非淋球菌和非脑膜炎球菌奈瑟菌,部分构成了口咽部微生物群,最近关于侵袭性感染的报道有所增加。我们对由巴氏奈瑟菌引起的 IE 进行了文献综述,发现β-内酰胺类抗生素有效,且预后相对较好。据我们所知,这是第一例通过 16S rRNA 分析鉴定出杆菌噬菌体的培养阴性 IE 病例。
{"title":"Culture-negative infective endocarditis due to Neisseria bacilliformis identified via 16S rRNA gene analysis from resected valve tissue: Case report and review of the literature.","authors":"Yoshinori Takahashi, Junya Nakade, Yoshitaka Zaimoku, Naoki Watanabe, Tomohisa Watari, Yoshihito Otsuka, Yasunori Iwata, Hajime Kanamori","doi":"10.1016/j.jiac.2024.08.017","DOIUrl":"10.1016/j.jiac.2024.08.017","url":null,"abstract":"<p><p>Blood culture-negative infective endocarditis (BCNE) has a poorer prognosis than culture-positive cases. Thus, it is crucial to determine the pathogenic microorganism using molecular diagnostic techniques, in addition to conventional techniques, including cultures of blood and/or resected valve tissue. Herein, we report a case of culture-negative infective endocarditis (IE) caused by Neisseria bacilliformis, as identified by 16S rRNA analysis of valve tissue. N. bacilliformis a non-gonococcal and non-meningococcal Neisseria species that partially comprises the oropharyngeal microbiome, and reports of invasive infections have increased recently. We conducted a literature review of IE caused by N. bacilliformis and found that beta-lactam antibiotics were effective with a relatively favorable prognosis. To the best of our knowledge, this is the first case of culture-negative IE in which N. bacilliformis was identified via 16S rRNA analysis.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102502"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dilated common bile duct diameter as an indicator of bacteremia in patients with symptomatic common bile duct stones. 胆总管直径扩张作为症状性胆总管结石患者菌血症的指标。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-12-03 DOI: 10.1016/j.jiac.2024.12.001
Kazuharu Kawano, Takayuki Otani, Toshikazu Abe, Toshihisa Ichiba, Keisuke Maeda, Yuji Okazaki, Hiroshi Naito

Background: The optimal timing and selection for blood culture collection in patients with acute cholangitis remains unclear. The relationship between common bile duct (CBD) diameter and the incidence of bacteremia in patients with CBD stones was elucidated.

Methods: This single-center retrospective observational study included patients with symptomatic CBD stones who presented to the emergency department between January 2019 and December 2021. The primary endpoint was the incidence of bacteremia. The patients were divided into two groups based on bacteremia complications. The patient characteristics and CBD diameters were compared between the two groups to identify factors associated with bacteremia.

Results: In total, 270 patients were analyzed, with bacteremia identified in 134 patients (50 %), and the median CBD diameter was 10.7 mm (IQR, 8.7-13.7). The CBD diameter was significantly larger in patients with bacteremia (median 12.4 mm [IQR, 9.9-15.7] vs. 9.7 mm [IQR, 8.2-11.7], P < 0.001) in univariate analysis. Multivariable analysis revealed that the CBD diameter was significantly associated with bacteremia (OR: 1.25, 95 % CI: 1.14-1.38, P < 0.010). The area under the ROC curves, representing the diagnostic accuracy of CBD diameter for indicating bacteremia, was 0.72 (95 % CI, 0.66-0.78) with a cut-off value of 11.2 mm.

Conclusion: CBD dilation in patients with symptomatic CBD stones is significantly correlated with bacteremia. The CBD diameter cannot be assessed as the sole tool for detecting bacteremia; however, CBD dilation could be an indicator of bacteremia, assisting in the treatment strategy, regardless of the initial severity of cholangitis.

背景:急性胆管炎患者血培养采集的最佳时机和选择尚不清楚。探讨胆总管(CBD)直径与胆总管结石患者菌血症发生率的关系。方法:这项单中心回顾性观察研究纳入了2019年1月至2021年12月期间就诊于急诊科的症状性CBD结石患者。主要终点是菌血症的发生率。根据菌血症并发症将患者分为两组。比较两组患者的特征和CBD直径,以确定与菌血症相关的因素。结果:共分析270例患者,134例(50%)发现菌血症,中位CBD直径为10.7 mm (IQR, 8.7-13.7)。菌血症患者的CBD直径明显增大(中位数12.4 mm [IQR, 9.9-15.7] vs. 9.7 mm [IQR, 8.2-11.7]), P结论:症状性CBD结石患者的CBD扩张与菌血症显著相关。CBD直径不能作为检测菌血症的唯一工具;然而,无论初始胆管炎的严重程度如何,CBD扩张可能是菌血症的一个指标,有助于治疗策略。
{"title":"Dilated common bile duct diameter as an indicator of bacteremia in patients with symptomatic common bile duct stones.","authors":"Kazuharu Kawano, Takayuki Otani, Toshikazu Abe, Toshihisa Ichiba, Keisuke Maeda, Yuji Okazaki, Hiroshi Naito","doi":"10.1016/j.jiac.2024.12.001","DOIUrl":"10.1016/j.jiac.2024.12.001","url":null,"abstract":"<p><strong>Background: </strong>The optimal timing and selection for blood culture collection in patients with acute cholangitis remains unclear. The relationship between common bile duct (CBD) diameter and the incidence of bacteremia in patients with CBD stones was elucidated.</p><p><strong>Methods: </strong>This single-center retrospective observational study included patients with symptomatic CBD stones who presented to the emergency department between January 2019 and December 2021. The primary endpoint was the incidence of bacteremia. The patients were divided into two groups based on bacteremia complications. The patient characteristics and CBD diameters were compared between the two groups to identify factors associated with bacteremia.</p><p><strong>Results: </strong>In total, 270 patients were analyzed, with bacteremia identified in 134 patients (50 %), and the median CBD diameter was 10.7 mm (IQR, 8.7-13.7). The CBD diameter was significantly larger in patients with bacteremia (median 12.4 mm [IQR, 9.9-15.7] vs. 9.7 mm [IQR, 8.2-11.7], P < 0.001) in univariate analysis. Multivariable analysis revealed that the CBD diameter was significantly associated with bacteremia (OR: 1.25, 95 % CI: 1.14-1.38, P < 0.010). The area under the ROC curves, representing the diagnostic accuracy of CBD diameter for indicating bacteremia, was 0.72 (95 % CI, 0.66-0.78) with a cut-off value of 11.2 mm.</p><p><strong>Conclusion: </strong>CBD dilation in patients with symptomatic CBD stones is significantly correlated with bacteremia. The CBD diameter cannot be assessed as the sole tool for detecting bacteremia; however, CBD dilation could be an indicator of bacteremia, assisting in the treatment strategy, regardless of the initial severity of cholangitis.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102571"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Selection and evaluation of suitable quality control strains for meropenem antimicrobial susceptibility testing through preliminary external quality assessment. 通过初步外部质量评估,为美罗培南抗菌药物敏感性测试选择和评估合适的质量控制菌株。
IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES Pub Date : 2025-02-01 Epub Date: 2024-11-06 DOI: 10.1016/j.jiac.2024.11.003
Junichi Hirayama, Kotaro Aoki, Kohji Komori, Yo Sugawara, Chika Arai, Yoshikazu Ishii, Motoyuki Sugai, Kazuhiro Tateda

Background: Quality control (QC) of carbapenem susceptibility testing for Gram-negative bacteria faces challenges due to limited measuring ranges and the lack of suitable QC strains. This study aimed to select and evaluate QC strains for meropenem antimicrobial susceptibility testing (AST) through a pilot external quality assessment (EQA).

Methods: Candidate QC strains for meropenem AST were selected based on primary AST data and genomic information from the Japan Antimicrobial Resistant Bacterial Bank. Phenotype stability was verified through serial passaging and MIC comparison with original strains. The validated broth microdilution method was used to determine the target MIC value in a pilot EQA involving 47 clinical laboratories in Japan using ten different AST methods.

Results: Two strains, Citrobacter freundii JBBDAJB-19-0032 (Strain-A) and Enterobacter hormaechei subsp. steigerwaltii JBEBAAB-19-0102 (Strain-B), both carrying blaIMP-1, were selected as candidate QC strains. The meropenem MICs for Strain-A and Strain-B were 4 mg/L and 2 mg/L, respectively. In the pilot EQA, 43 laboratories reported appropriate results for Strain-A and 40 laboratories reported appropriate results for Strain-B. The MIC range was 2-8 mg/L for Strain-A and 1-4 mg/L for Strain-B. However, 19 and 12 laboratories, respectively, reported out-of-range MICs using AST plates on the MicroScan WalkAway. Inappropriate results were reported by four and seven laboratories, respectively, using common methods for Strain-A and Strain-B, respectively.

Conclusions: The candidate QC strains selected for this study are suitable for meropenem AST EQA, except when the measuring range of certain methods does not match their QC range.

背景:由于测量范围有限和缺乏合适的质控菌株,革兰氏阴性菌碳青霉烯类药敏试验的质控(QC)面临挑战。本研究旨在通过试点外部质量评估(EQA),选择和评估美罗培南抗菌药物敏感性检测(AST)的质控菌株:方法: 根据 AST 原始数据和日本抗菌药物耐药性细菌库的基因组信息,筛选出用于美罗培南 AST 的 QC 候选菌株。通过连续传代和与原始菌株的 MIC 比较来验证表型的稳定性。在一项试点 EQA 中,使用经过验证的肉汤微量稀释法确定目标 MIC 值,这项试点 EQA 涉及日本 47 个临床实验室,使用了 10 种不同的 AST 方法:结果:两株均携带 blaIMP-1 的柠檬酸杆菌 JBBDAJB-19-0032(菌株-A)和肠杆菌 hormaechei 亚种 steigerwaltii JBEBAAB-19-0102(菌株-B)被选为候选质控菌株。菌株-A 和菌株-B 的美罗培南 MIC 值分别为 4 mg/L 和 2 mg/L。在试点 EQA 中,43 个实验室报告了菌株 A 的适当结果,40 个实验室报告了菌株 B 的适当结果。菌株 A 的 MIC 范围为 2-8 mg/L,菌株 B 为 1-4 mg/L。然而,分别有 19 和 12 个实验室报告了使用 MicroScan WalkAway 上的 AST 平板的 MIC 值超出范围。使用普通方法检测菌株 A 和菌株 B 时,分别有 4 家和 7 家实验室报告了不恰当的结果:本研究选择的候选质控菌株适用于美罗培南 AST EQA,除非某些方法的测量范围与其质控范围不匹配。
{"title":"Selection and evaluation of suitable quality control strains for meropenem antimicrobial susceptibility testing through preliminary external quality assessment.","authors":"Junichi Hirayama, Kotaro Aoki, Kohji Komori, Yo Sugawara, Chika Arai, Yoshikazu Ishii, Motoyuki Sugai, Kazuhiro Tateda","doi":"10.1016/j.jiac.2024.11.003","DOIUrl":"10.1016/j.jiac.2024.11.003","url":null,"abstract":"<p><strong>Background: </strong>Quality control (QC) of carbapenem susceptibility testing for Gram-negative bacteria faces challenges due to limited measuring ranges and the lack of suitable QC strains. This study aimed to select and evaluate QC strains for meropenem antimicrobial susceptibility testing (AST) through a pilot external quality assessment (EQA).</p><p><strong>Methods: </strong>Candidate QC strains for meropenem AST were selected based on primary AST data and genomic information from the Japan Antimicrobial Resistant Bacterial Bank. Phenotype stability was verified through serial passaging and MIC comparison with original strains. The validated broth microdilution method was used to determine the target MIC value in a pilot EQA involving 47 clinical laboratories in Japan using ten different AST methods.</p><p><strong>Results: </strong>Two strains, Citrobacter freundii JBBDAJB-19-0032 (Strain-A) and Enterobacter hormaechei subsp. steigerwaltii JBEBAAB-19-0102 (Strain-B), both carrying bla<sub>IMP-1</sub>, were selected as candidate QC strains. The meropenem MICs for Strain-A and Strain-B were 4 mg/L and 2 mg/L, respectively. In the pilot EQA, 43 laboratories reported appropriate results for Strain-A and 40 laboratories reported appropriate results for Strain-B. The MIC range was 2-8 mg/L for Strain-A and 1-4 mg/L for Strain-B. However, 19 and 12 laboratories, respectively, reported out-of-range MICs using AST plates on the MicroScan WalkAway. Inappropriate results were reported by four and seven laboratories, respectively, using common methods for Strain-A and Strain-B, respectively.</p><p><strong>Conclusions: </strong>The candidate QC strains selected for this study are suitable for meropenem AST EQA, except when the measuring range of certain methods does not match their QC range.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102553"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Infection and Chemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1